Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > In normal market reaction the SP should have gone up

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Oct 10, 2024 7:54pm

66 Views

Post# 36261945

RE:RE:RE:RE:In normal market reaction the SP should have gone up

Yes the numbers and the call was pretty good but he was confident about many things before. They don't control the FDA and the supplier... they should have had at least 6 to 9 months of Egrifta on hand but nope they did'nt. Likewise th1902 does'nt look like a game changer from the tone of Christian voice. The analyst is prudent unlike the management.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?